TPTX - Turning Point posts data from early-stage TPX-0046 cancer study

Turning Point Therapeutics (TPTX) posted positive initial clinical data from the ongoing Phase 1/2 SWORD-1 study of its RET inhibitor drug candidate, TPX-0046, for the treatment of certain types of cancer.In the study, a total of 21 patients with RET-altered non-small cell lung cancer ((NSCLC)) or medullary thyroid carcinoma ((MTC)) were treated with TPX-0046 across multiple doses and schedules from 10mg once daily ((QD)) to 30mg QD.The initial data from the Phase 1 dose finding portion showed preliminary clinical activity, including objective responses and a generally well-tolerated safety profile.Turning Point continues to evaluate doses and schedules to determine a recommended Phase 2 dose, and plans to revise the study protocol to include Phase 1 expansion cohorts.After determining the recommended Phase 2 dose, the company plans to study TPX-0046 in multiple Phase 1 dose expansion cohorts in up to 75 patients with RET-altered malignancies prior to an end of Phase 1 meeting with the FDA.

For further details see:

Turning Point posts data from early-stage TPX-0046 cancer study